Aberdeen Group’s G1 Therapeutics GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-423,869
Closed -$966K – 978
2024
Q2
$966K Hold
423,869
– – ﹤0.01% 822
2024
Q1
$1.83M Hold
423,869
– – ﹤0.01% 784
2023
Q4
$1.29M Buy
+423,869
New +$796K ﹤0.01% 816

Aberdeen Group's GTHX Position: Q3 2024 in Review

Aberdeen Group sold out of G1 Therapeutics (GTHX) in Q3 2024, closing a stake of 423,869 shares — an estimated $966K sold.

Aberdeen Group first reported a position in GTHX in Q4 2023 and held it in 3 quarters. The position peaked at $1.83M in Q1 2024. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Aberdeen Group reported no remaining G1 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Aberdeen Group sold 423,869 G1 Therapeutics shares in Q3 2024, an estimated $966K.
  • Aberdeen Group first reported a position in G1 Therapeutics in Q4 2023 and held it in 3 quarters.
  • Aberdeen Group's G1 Therapeutics position peaked at $1.83M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics as of Q3 2024.

Based on Aberdeen Group's 13F filing for Q3 2024, filed 25 Oct 2024.